Drug intelligence / Profile preview

CDDD2-94

Development stage: Preclinical
Lead developer: University of South Australia Cancer Research Institute
Modality: Small Molecules
Administration: Not Determined

Overview

CDDD2-94 is a potent, highly selective inhibitor of cyclin-dependent kinase 4 (CDK4), with a Ki of 2 nM and over 140-fold selectivity for CDK4 compared to CDK6 (Ki = 279 nM)[3]. It arrests the cell cycle in the G1/G0 phase, induces senescence, and inhibits proliferation of Rb-proficient ovarian cancer cells[1][3][5]. CDDD2-94 shows synergistic anti-proliferative effects in combination with mTOR, MEK, PI3K, or PARP inhibitors[1]. In preclinical mouse models, it delays tumor growth and increases survival with low hematologic toxicity compared to palbociclib[1][5].

Targets

CDK4 (Cyclin-dependent kinase 4)

Beyond the preview

Go deeper on CDDD2-94.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDDD2-94.

Explore the full profile